{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:46:38Z","timestamp":1776746798973,"version":"3.51.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Delayed platelet engraftment remains a major limitation of autologous stem cell transplantation (ASCT) for plasma-cell neoplasms. Romiplostim N01, a thrombopoietin receptor agonist, may enhance early megakaryocytic recovery, while the use of non-cryopreserved peripheral blood stem cells (PBSCs) eliminates dimethyl-sulfoxide\u2013related toxicity and reduces procedural cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study evaluated 15 patients receiving non-cryopreserved PBSCs and early Romiplostim N01 after ASCT and compared them with 21 historical controls who received cryopreserved PBSCs and recombinant human thrombopoietin. We tried to compare time to engraftment, transfusion burden, hospitalization duration and cost, safety, hematologic responses and survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Platelet engraftment occurred significantly earlier in the Romiplostim N01 cohort (median 11 vs. 13 days;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.008), and complete platelet recovery by day +30 was higher (100% vs. 66.7%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.027). Neutrophil recovery, transfusion requirements, and hospitalization duration were comparable between groups. Total hospitalization cost was markedly lower with Romiplostim N01 (77, 609 \u00b1 21, 624 vs. 106, 188 \u00b1 14, 910 CNY;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001). The two patient groups also demonstrated comparable safety profiles, treatment responses, and survival outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Romiplostim N01 safely accelerates thrombopoietic recovery and substantially reduces cost when combined with non-cryopreserved PBSCs. This strategy represents a practical and economically favorable supportive-care model for ASCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1813060","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:48Z","timestamp":1776745368000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Romiplostim N01 accelerates platelet engraftment in autologousstem cell transplantation using non-cryopreserved peripheral blood stem cells for plasma cell neoplasms"],"prefix":"10.3389","volume":"17","author":[{"given":"Xianfu","family":"Sheng","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qijia","family":"Zheng","sequence":"additional","affiliation":[{"name":"The First Medical College of Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanxi","family":"Dong","sequence":"additional","affiliation":[{"name":"The First Medical College of Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuechao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Laboratory, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.24976\/Discov.Med.202436188.162","article-title":"Current and emerging immunotherapies for systemic AL amyloidosis","volume":"36","author":"Moreno","year":"2024","journal-title":"Discov Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02490-1","article-title":"Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"60","author":"Grieb","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.06.009","article-title":"Role of autologous stem cell transplantation in systemic light chain amyloidosis","volume":"24","author":"Parmar","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000896","article-title":"The role of stem cell transplantation in the modern management of multiple myeloma","volume":"32","author":"Villar","year":"2025","journal-title":"Curr Opin Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S463384","article-title":"Thrombopoietin receptor agonists in post-hematopoietic cell transplantation complicated by prolonged thrombocytopenia: a comprehensive review","volume":"13","author":"Elsayed","year":"2024","journal-title":"Immunotarg Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12791","article-title":"Transfusion-related adverse events in the Platelet Dose study","volume":"55","author":"Kaufman","year":"2015","journal-title":"Transfusion"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20230409-00575","article-title":"Consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition)","volume":"103","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jtct.2024.12.015","article-title":"Comparison of thrombopoietin receptor agonists plus recombinant human thrombopoietin versus recombinant human thrombopoietin alone for hematopoietic reconstruction in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation","volume":"31","author":"Xu","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2024.103972","article-title":"Recombinant human thrombopoietin improves platelet engraftment after autologous hematopoietic stem cell transplantation in patients with aggressive lymphoma","volume":"63","author":"Qiu","year":"2024","journal-title":"Transf Apher Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19954","article-title":"Increasing the dose of recombinant human thrombopoietin can enhance platelet engraftment after allogeneic haematopoietic stem cell transplantation: a NICHE cohort study","volume":"206","author":"Feng","year":"2025","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S299591","article-title":"A review of romiplostim mechanism of action and clinical applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1929957","article-title":"Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation","volume":"62","author":"Pasvolsky","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.002","article-title":"A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation","volume":"19","author":"Liesveld","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.003","article-title":"Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation","volume":"26","author":"Mahat","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000358","article-title":"Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1\/2 multicenter trial","volume":"135","author":"Peffault de Latour","year":"2020","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.223966","article-title":"Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial","volume":"105","author":"Zaninetti","year":"2020","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.31547\/bct-2024-017","article-title":"Eltrombopag enhances recovery from cytopenias due to poor graft function after hematopoietic cell transplantation","volume":"8","author":"Halahleh","year":"2025","journal-title":"Blood Cell Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002971","article-title":"Eltrombopag for treatment of thrombocytopenia after autologous stem cell transplantation in children: single center experience","volume":"47","author":"Bayram","year":"2025","journal-title":"J Pediatr Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007838","article-title":"Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76164","article-title":"Romiplostim reduces platelet transfusion needs in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"16","author":"Surya Prakash","year":"2024","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27233","article-title":"Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: results of a phase II study","volume":"99","author":"Ahmed","year":"2024","journal-title":"Am J Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1340908","article-title":"Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41409-024-02431-y","article-title":"Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation","volume":"60","author":"Bekadja","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.12.016","article-title":"Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry","volume":"23","author":"Bekadja","year":"2021","journal-title":"Cytotherapy"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.938595","article-title":"Non-cryopreserved peripheral blood stem cell graft for autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma patients","volume":"28","author":"Noiperm","year":"2023","journal-title":"Ann Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17090","article-title":"Non-cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma","volume":"62","author":"Araujo","year":"2022","journal-title":"Transfusion"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2020.03.006","article-title":"Non-cryopreserved peripheral blood stem cells autologous transplantation in multiple myeloma: bicentric study","volume":"27","author":"Jennane","year":"2020","journal-title":"Transf Clin Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B31","first-page":"67","article-title":"Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01718-2","article-title":"Cryopreserved versus non-cryopreserved stem cell autografts in multiple myeloma a restrospective cohort study","volume":"57","author":"Pessoa","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.927084","article-title":"Outcomes of non-cryopreserved versus cryopreserved peripheral blood stem cells for autologous stem cell transplantation in multiple myeloma","volume":"25","author":"Piriyakhuntorn","year":"2020","journal-title":"Ann Transplant"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2020-143049","article-title":"Fresh versus cryopreserved peripheral stem cell for autologous transplantation in multiple myeloma: an analysis of short-term outcomes","volume":"136","author":"Joseph","year":"2020","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1141-8","article-title":"Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells","volume":"90","author":"Kemp","year":"2011","journal-title":"Ann Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy-induced thrombocytopenia: a review of the literature","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1960979","article-title":"Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP)","volume":"21","author":"Chen","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043665","article-title":"Successful treatment of refractory cancer therapy-induced thrombocytopenia in a breast cancer patient using romiplostim N01: a case report","volume":"104","author":"Liu","year":"2025","journal-title":"Med (Balt)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70105","article-title":"Multicenter single-blind randomized controlled trial of the romiplostim biosimilar","volume":"6","author":"Melikyan","year":"2025","journal-title":"EJHaem"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1813060\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:50Z","timestamp":1776745370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1813060\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1813060"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1813060","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1813060"}}